Erez Israeli warns that the administration's proposed generic drug tariffs will likely increase prices for American patients.
Erez Israeli, the chief executive of Dr. Reddy's Laboratories, stated that the administration's plan to impose tariffs on generic drugs will lead to price increases for consumers. The administration announced that imported generic drugs will face zero tariffs for two years starting August 1, followed by a 100% levy in August 2028 and a 200% levy the following year. The primary goal of the administration is to reshore generic pharmaceutical production to the United States. However, Israeli noted that because generic drugs are a low-margin business, companies may struggle to absorb the costs, likely passing the magnitude of the tariff directly to patients. Experts expressed skepticism regarding the timeline, noting that moving operations to the U.S. could take four to seven years. While the administration aims to strengthen domestic supply chains, some analysts warn that high production costs in the U.S. might not provide enough incentive for manufacturers to relocate, potentially leading to supply shortages if companies choose to exit the market.